Ernexa Therapeutics (ERNA) News Today $1.37 +0.06 (+4.58%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.36 -0.01 (-0.36%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Ernexa Therapeutics' (ERNA) "Sell (E+)" Rating Reiterated at Weiss Ratings3 hours ago | americanbankingnews.comErnexa Therapeutics (NASDAQ:ERNA) Trading Down 3.7% - Time to Sell?October 8 at 3:45 AM | americanbankingnews.comErnexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the MesaOctober 1, 2025 | globenewswire.comCritical Survey: Savara (NASDAQ:SVRA) and Ernexa Therapeutics (NASDAQ:ERNA)October 1, 2025 | americanbankingnews.comErnexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development SummitSeptember 29, 2025 | globenewswire.comErnexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer ResearchSeptember 17, 2025 | globenewswire.comErnexa Therapeutics Provides Update on Operational Excellence and PerformanceSeptember 10, 2025 | globenewswire.comErnexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comErnexa Therapeutics First Half 2025 Earnings: US$2.91 loss per share (vs US$33.78 loss in 1H 2024)August 15, 2025 | finance.yahoo.comErnexa Therapeutics Regains Compliance with Nasdaq for Continued ...July 11, 2025 | nasdaq.comErnexa Therapeutics Regains Compliance with Nasdaq ... - MorningstarJuly 11, 2025 | morningstar.comMErnexa Therapeutics Regains Compliance with Nasdaq Listing RequirementsJuly 9, 2025 | globenewswire.comErnexa Therapeutics changes independent auditor to Haskell & WhiteJuly 8, 2025 | investing.comErnexa Therapeutics Expands Scientific Advisory Board as It Prepares for Clinical Trials in Ovarian Cancer and Autoimmune Disease - NasdaqJune 27, 2025 | nasdaq.comErnexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical DevelopmentJune 25, 2025 | globenewswire.comErnexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase AgreementJune 24, 2025 | globenewswire.comErnexa Therapeutics Announces 1-for-15 Reverse Stock SplitJune 10, 2025 | globenewswire.comErnexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025May 28, 2025 | globenewswire.comErnexa Therapeutics Stock Short Interest Report | NASDAQ:ERNA | BenzingaMay 23, 2025 | benzinga.comErnexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical OperationsMay 14, 2025 | globenewswire.comErnexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025April 29, 2025 | globenewswire.comErnexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025April 22, 2025 | globenewswire.comErnexa Therapeutics files to sell 10.44M shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comErnexa Therapeutics Closes New Funding RoundApril 3, 2025 | globenewswire.comEterna changes name to Ernexa TherapeuticsMarch 27, 2025 | markets.businessinsider.comEterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune DiseaseMarch 25, 2025 | markets.businessinsider.comEterna hosts inaugural meeting of newly formed SABFebruary 26, 2025 | markets.businessinsider.comEterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy PipelineFebruary 26, 2025 | globenewswire.comEterna appoints Zeldis, Sather to scientific advisory boardJanuary 29, 2025 | markets.businessinsider.comEterna Therapeutics (NASDAQ:ERNA) Stock Quotes, Forecast and News SummaryJanuary 14, 2025 | benzinga.comEterna Announces Positive Preclinical Study Results On ERNA-101 In Ovarian Cancer; Stock Up 69%January 14, 2025 | markets.businessinsider.comEterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian CancerJanuary 14, 2025 | globenewswire.comEterna Therapeutics Appoints Dr. Elena Ratner To Board Of DirectorsJanuary 9, 2025 | markets.businessinsider.comEterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of DirectorsJanuary 9, 2025 | globenewswire.comGrowth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024-2035: A Forecasted $5.6 Billion LandscapeJanuary 9, 2025 | uk.finance.yahoo.comEterna Therapeutics Inc Ordinary SharesDecember 5, 2024 | morningstar.comMEterna launches research to evaluate ERNA-101December 3, 2024 | markets.businessinsider.comEterna Therapeutics Authorized $1 Mln Share Buyback; Stock Up In Pre-marketNovember 25, 2024 | markets.businessinsider.comEterna Therapeutics Announces Up to $1 Million Stock Repurchase ProgramNovember 25, 2024 | markets.businessinsider.comEterna regains compliance with NasdaqNovember 14, 2024 | markets.businessinsider.comEterna Therapeutics Regains Compliance with NASDAQ for Continued ListingNovember 14, 2024 | globenewswire.comEterna files to sell 49.87M shares of common stock for holdersNovember 7, 2024 | markets.businessinsider.comEterna completes strategic financial restructuringOctober 31, 2024 | markets.businessinsider.comEterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term SuccessOctober 30, 2024 | globenewswire.comEterna, Factor announce license, collaboration agreementOctober 19, 2024 | finance.yahoo.comEterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare DiseasesOctober 17, 2024 | globenewswire.comCoeptis Therapeutics (NASDAQ:COEP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comEterna Therapeutics Inc. (ERNA)September 18, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 10, 2024 | globenewswire.comEterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardMay 8, 2024 | globenewswire.com Get Ernexa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERNA Media Mentions By Week ERNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERNA News Sentiment▼0.000.63▲Average Medical News Sentiment ERNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERNA Articles This Week▼31▲ERNA Articles Average Week Get the Latest News and Ratings for ERNA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ernexa Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies RANI News EGRX News ATHE News SONN News AKTX News TENX News ITRM News ALVR News PYRGF News KLTO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERNA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
